SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolismAnna Polak, Przemysław Juszczyński, Monika Noyszewska‐Kania et al.|Cell Death and Disease|2020Cited by 41
Persistent imbalance, anti-apoptotic, and anti-inflammatory signature of circulating C-C chemokines and cytokines in patients with paroxysmal nocturnal hemoglobinuriaUrszula Szlendak, Jacek Nowak, Beata Krzymieniewska et al.|Cytokine|2021Cited by 1
Abstract 3324: Optimizing the therapeutic potential of tyrosine kinase inhibitors in chemo-immunotherapy of B-cell acute lymphoblastic leukemia involving rituximabKrzysztof Domka, Małgorzata Firczuk, Martyna Poprzeczko et al.|Cancer Research|2022Cited by 1
Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical modelsKrzysztof Domka, Małgorzata Firczuk, Agnieszka Dąbkowska et al.|Haematologica|2024Cited by 1
PS986 SYK‐DEPENDENT P‐STAT5 ACTIVITY IS REQUIRED TO MAINTAIN CLONOGENIC POTENTIAL AND OXPHOS METABOLISM IN ACUTE MYELOID LEUKEMIA (AML) CELLSAnna Polak, Przemysław Juszczyński, Emilia Białopiotrowicz et al.|HemaSphere|2019Cited by 0